Chemours Co Stock Today
| CC Stock | USD 15.80 0.35 2.17% |
PerformanceVery Weak
| Odds Of DistressLow
|
Chemours is trading at 15.80 as of the 25th of February 2025, a 2.17% down since the beginning of the trading day. The stock's open price was 16.15. Chemours has only a 7 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. Note, on November 7, 2017, Senator Tammy Duckworth of US Senate acquired under $15k worth of Chemours's common stock.
Business Domain Materials | IPO Date 1st of July 2015 | Category Basic Materials |
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. The Chemours Company was founded in 2014 and is headquartered in Wilmington, Delaware. Chemours operates under Specialty Chemicals classification in the United States and is traded on New York Stock Exchange. The company has 149.44 M outstanding shares of which 7.27 M shares are currently sold short in the market by investors with about 4.5 days to cover all shorted shares. More on Chemours Co
Moving together with Chemours Stock
Chemours Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Mark Vergnano | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | Showing 3 out of 6 themes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Credit Industriel et Commercial SA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Diversified Chemicals, Specialty Chemicals, Basic Materials, NYSE Composite, SP Midcap 400, Plastics, Chemicals Makers, Synthetics, Trump Equities, SRI Sustainable Growth, Chemicals, Materials, Chemicals, Specialty Chemicals, Basic Materials (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsChemours can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Chemours' financial leverage. It provides some insight into what part of Chemours' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Chemours Co (CC) is traded on New York Stock Exchange in USA. It is located in 1007 Market Street, Wilmington, DE, United States, 19899 and employs 6,000 people. Chemours is listed under Diversified Chemicals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a market capitalization of 2.5 B. Chemours is active under Chemicals sector as part of Materials industry. The entity has 149.44 M outstanding shares of which 7.27 M shares are currently sold short in the market by investors with about 4.5 days to cover all shorted shares.
Chemours Co reports about 1.1 B in cash with (633 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.73.
Check Chemours Probability Of Bankruptcy
Ownership AllocationChemours holds a total of 149.44 Million outstanding shares. The majority of Chemours Co outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Chemours to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Chemours. Please pay attention to any change in the institutional holdings of Chemours Co as this could imply that something significant has changed or is about to change at the company. On November 7, 2017, Senator Tammy Duckworth of US Senate acquired under $15k worth of Chemours's common stock.
Check Chemours Ownership Details
Chemours Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ubs Group Ag | 2024-12-31 | 2.1 M | |
| Norges Bank | 2024-12-31 | 1.8 M | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.8 M | |
| American Century Companies Inc | 2024-12-31 | 1.6 M | |
| Massachusetts Financial Services Company | 2024-12-31 | 1.6 M | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.6 M | |
| Vision One Management Partners Lp | 2024-12-31 | 1.6 M | |
| Scopia Management Inc | 2024-12-31 | 1.4 M | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 1.3 M | |
| Blackrock Inc | 2024-12-31 | 16.8 M | |
| Vanguard Group Inc | 2024-12-31 | 15.2 M |
Chemours Historical Income Statement
Chemours Stock Against Markets
Chemours Corporate Directors
| Curtis Anastasio | Independent Director | Profile | |
| Curtis Crawford | Independent Director | Profile | |
| Mary Cranston | Independent Director | Profile | |
| Bradley Bell | Independent Director | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chemours Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Diversified Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chemours. If investors know Chemours will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chemours listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.65) | Dividend Share 1 | Earnings Share 0.57 | Revenue Per Share | Quarterly Revenue Growth (0.01) |
The market value of Chemours is measured differently than its book value, which is the value of Chemours that is recorded on the company's balance sheet. Investors also form their own opinion of Chemours' value that differs from its market value or its book value, called intrinsic value, which is Chemours' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemours' market value can be influenced by many factors that don't directly affect Chemours' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemours' value and its price as these two are different measures arrived at by different means. Investors typically determine if Chemours is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemours' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.